Eiju Negoro, Takahiro Yamauchi, Noriko Fukuhara, Kazuhito Yamamoto, Toshiki Uchida, Koji Izutsu, Dai Maruyama, Yasuhito Terui, Hideaki Nakajima, Kiyoshi Ando, Youko Suehiro, Ilseung Choi, Nobuhiro Kanemura, Nobuhiko Nakamura, Go Yamamoto, Yoshinobu Maeda, Hirohiko Shibayama, Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai, Hwei-Fang Tien, Yok-Lam Kwong, Won-Seog Kim, Kensei Tobinai
A Japanese subgroup analysis from the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) was performed to evaluate the efficacy and safety outcomes of the Japanese population. In this Asian phase II study, darinaparsin was administered to 65 patients, including 37 Japanese patients. In the Japanese population, the histopathological type of PTCL was PTCL, not otherwise specified in 26 patients (70.3%), angioimmunoblastic T-cell lymphoma in 9 patients (24...
2023: Journal of Clinical and Experimental Hematopathology: JCEH